Moderna, an American biotechnology company, stated that the company has begun a study testing the coronavirus vaccine in adolescents as young as 12, expecting to be done in September 2021, according to Moderna’s CEO Stephane Bancel.
Last December, the U.S. and EU Food and Drug Administration gave a greenlight to Moderna’s vaccine for an emergency use for people aged 18 years or over.
Now, Moderna will advance into developing a vaccine for teenagers in which the study is expected to be done in September. However, Moderna’s CEO stated that the study for younger children between ages 1 and 11 will begin soon, but would take much longer as children’s immune systems could give a different response than adults. The clinical data in young children was not expected to be complete before 2022.